Minnesota led the way on insulin affordability, culminating in 2020 with Tim Walz's signing of a law to cut costs.

This post was written and published as a collaboration between the in-house editorial team at Benzinga and Corp. with ...

Eli Lilly explores expanding its weight-loss drugs, Mounjaro and Zepbound, to individuals with a BMI below 27 to prevent ...

The company is set to become the first $1tn drugmaker, but investors see warning signs it has reached ‘peak enthusiasm’ ...

In a groundbreaking move, Eli Lilly LLY is set to test its weight-loss medications on individuals who are not overweight but are at risk of gaining weight.

By integrating ultra-rapid acting insulin such as Lyumjev, which responds faster than traditional insulin, Tandem Diabetes ...

From Eli Lilly to Karuna Therapeutics to current owner Bristol Myers Squibb, the newly approved schizophrenia drug had quite ...

Six 2025 Lilly Endowment Community Scholar finalists have been selected by the Steuben County Community Foundation, it was ...

The longshoreman’s strike shutting down ports along the East and Gulf Coasts may cause a significant shortage of widely used ...

Aurobindo Pharma receives USFDA approval for Cephalexin tablets, expected to launch in Q3FY25 with CGT designation.

Aurobindo Pharma gains FDA approval for Cephalexin Tablets, bioequivalent to Keflet, with CGT designation and shared exclusivity.

The startup will be headed by CEO Ron Renaud, who previously led Cerevel Therapeutics — a developer of drugs for neurological conditions — and oversaw its acquisition by AbbVie in an $8.7 billion deal ...